

# Index

Page numbers followed by an f refer to figures. Page numbers followed by a t refer to tables.

## A

- acetoacetic acid ketone accumulation, in diabetic ketoacidosis (DKA), 60
- acetone.ketones accumulation, in diabetic ketoacidosis (DKA), 60
- acromegaly presenting with diabetic ketoacidosis (DKA), 47–48
  - IGF-1 levels linear relationship with HbA1c (A1C), 48, 48f, 49
  - laboratory testing results, 47
  - pituitary macro-adenoma and, 47
  - rarity of, 48, 49
  - trans-sphenoidal pituitary resection for, 47
- acute febrile neutrophilic dermatosis. See Sweet's syndrome
- adrenal steroidogenesis inhibitors
  - medical therapy, for Cushing's Disease (CD), 35
- alcohol abuse, type 1 diabetes (T1D) and, 148
- alpelisib therapy, 86, 88
  - phosphatidylinositol 3-kinase (PI3K) inhibition due to, 87
- alpelisib-induced hyperglycemia, 86–87
  - laboratory test results, 86
  - metformin therapy, 86, 88
  - PIK3CA mutation, 86
- American Diabetes Association (ADA)
  - dietary recommendations of, 73
  - on gestational diabetes screening, 107
  - on latent autoimmune diabetes in adults (LADA) within type 1 diabetes (T1D) classification, 116
  - on low-carbohydrate diets, 63
  - type 2 diabetes (T2D) medical management algorithm, 163
- antibiotic use, refractory hypoglycemia due to, 150–152, 151t
- antibody-positive diabetes, postpartum, 108
- autoimmune (AI) diabetes, 14
  - autoantibodies testing for, 119
  - $\beta$ -cell function recovery, 81
  - features of, 13
  - GAD65 antibodies and, 118
  - immune checkpoint inhibitor (ICI) therapy cause of, 51–52, 61, 80–81, 84
- autoimmune (AI) diabetes, lupus flare cause of, 118
- laboratory test results, 118, 119t
- autoimmune (AI) diabetes, onset during pregnancy, 107
- laboratory test results, 107
- latent autoimmune diabetes in adults (LADA) and, 108, 109f
- positive GAD antibodies and, 109, 109f
- type 1 diabetes (T1D) education, 108
- autoimmune (AI) diabetes illusion, 114–115

laboratory test results, 114, 115t  
 autoimmune diseases  
   development of multiple, 118–119  
   glucocorticoid therapy for, 135  
   latent autoimmune diabetes in  
   adults (LADA) autoimmune  
   markers, 115  
   with type 1 diabetes (T1D), 9, 112  
   types of, 112  
 autoimmune hepatitis, type B insulin  
   resistance (TBIR) with, 97–98,  
   98t, 99f, 100–102, 100f  
 automated insulin infusion system, for  
   blood glucose concentration  
   control in type 1 diabetes (T1D),  
   132  
   function of, 132–133  
   on glycemic trend and time in  
   range (TRI), 133f  
   MiniMed 670G, 132, 133, 134  
   patient COVID-19 virus and,  
   132–133, 134  
 autosomal-dominant familial diabetes,  
   Maturity-Onset Diabetes of the  
   Young (MODY) as, 38

## B

basal insulin with glucagon-like  
   peptide-1 receptor agonists  
   (GLP-IRAs), basal-bolus insulin  
   therapy transition to, 163–164  
 basal-bolus insulin therapy, 8, 50, 71,  
   72  
   transition to basal insulin with  
   glucagon-like peptide-1 receptor  
   agonists (GLP-IRAs), 163–164  
   for type 1 diabetes (T1D), 82  
 $\beta$ -cell. *See also* pancreatic  $\beta$ -cell  
   dysfunction  
   autoimmune (AI) diabetes  
   function recovery of, 81  
   immune checkpoint inhibitor  
   (ICI) diabetes and partial  
   destruction of, 80, 81–82, 81f, 85  
   immune checkpoint inhibitor  
   (ICI) induced diabetes and  
   function recovery of, 84

insulin secretion, 147  
 $\beta\beta$ -hydroxybutyric acid ketone  
   accumulation, in diabetic  
   ketoacidosis (DKA), 60  
 blood glucose  
   concentration control, with  
     automated insulin infusion  
     system, 132, 133–134, 133f  
   pembrolizumab effect on levels of,  
     81–82, 81f  
   in type B insulin resistance  
   (TBIR), with lupus nephritis  
   and autoimmune hepatitis,  
     99f  
 breast cancer, 91–92, 94, 96, 150  
   phosphatidylinositol 3-kinase  
   (PI3K) inhibitor with  
   fulvestrant for, 90, 93  
 bullous pemphigoid, dipeptidyl  
   peptidase-4 inhibitors association  
   with, 28

## C

cancer  
   breast, 90–94, 96, 150  
   clear cell carcinoma, 50–51  
   clival metastasis, 20, 21  
   immune checkpoint inhibitor  
     (ICI) therapy for, 50–51, 52,  
     77–78  
   lung, 77–78, 83–85  
   lung and bone, 86–88  
   melanoma, 80–82  
   pancreatic, 18, 20–22  
   PI3K/ACT pathway mutations,  
     94  
 cardiovascular disease  
   diabetes and prevalence of, 199–  
     201  
   glucagon-like peptide-1 receptor  
   agonist (GLP-1RA)  
   treatment for protection  
   from, 165, 193  
 catabolism, as cystic fibrosis-related  
   diabetes (CFRD) result, 156, 157  
 childhood obesity, type 2 diabetes  
   (TD2) and, 9

- chronic obstructive pulmonary disease (COPD), 23
  - prednisone exacerbation of, 138
- Classic Sweet's syndrome, 26, 27t
- clear cell carcinoma, immune checkpoint inhibitor (ICI)
  - insulinopenic diabetes., 50–51
- clival metastasis, 20, 21
- computed tomography (CT) scan
  - for Cushing's Disease (CD), 33
  - for pancreatic adenocarcinoma, 20, 21, 22
- Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer (CPDPC), 22
- continuous glucose monitor (CGM), 72, 74, 91f, 92f
  - for cystic fibrosis-related diabetes (CFRD), 158, 159
  - for glucagon-like peptide 1 receptor agonists (GLP-IRAs), type 2 diabetes (T2D) on high-dose insulin therapy, 171–172
  - for immune checkpoint inhibitor (ICI) induced diabetes, 83
  - for variable insulin doses monitoring, 93
- continuous glucose monitor (CGM), with type 1 diabetes (T1D) and Down's syndrome, 123–124
- caregivers diabetes education, 125
- glycemic control improvement through, 124, 124t, 125
- hypoglycemic episodes findings, 123–125
- laboratory test results, 123
- time in range (TIR) and time below range (TBR) with, 124, 124t
- treatment for, 123
- continuous glucose monitor (CGM) patterns, of glucocorticoid-treated patient with diabetes, 135
- algorithm for management of, 140f
- clinical practice implications for, 139
- glucocorticoid therapy for
  - inflammatory and autoimmune diseases, 135
- laboratory test results, 135, 136f
- report before and after prednisone use, 136–137f
- treatment, 135
- continuous subcutaneous insulin infusion (CSII) pump, U-500 regular (U-500R) insulin in ambulatory glucose profile pre-intervention, 128f
- daily report example, 128f, 130f
- Evaluating U-500R Infusion Versus Injection in Type 2 Diabetes (VIVID) study, 127, 128–129
- faster-acting insulin aspart (FiAsp)
  - addition, 129, 130f
- laboratory test results, 127
- meal bolus need via, 129–130
- patient medical history, 127
- treatment, 127
- corticosteroids
  - for refractory hypoglycemia, 147
  - Sweet's syndrome challenge of, 27, 28
- cortisol, glucose tolerance and insulin insensitivity from, 34, 35
- COVID-19 virus
  - automated insulin infusion system and, 132–133, 134
  - euglycemic diabetic ketoacidosis (eDKA) treatment restrictions, 54–55
  - euglycemic diabetic ketoacidosis (eDKA) with, 54–55, 55f, 56, 57
  - obesity and diabetes risk factors, 177
  - persistent hyperglycemia in, 175
  - starvation ketosis and, 56
  - transient severe insulin resistance (IR) in prediabetes and, 175–177
- CTLA-4 role, in immune checkpoint inhibitor (ICI) insulinopenic diabetes, 51, 77–78, 83, 85

## Cushing's Disease (CD)

- adrenal steroidogenesis inhibitors
  - medical therapy for, 35
- computed tomography (CT) scan
  - and, 33
- cortisol influence on, 34, 35
- diabetes prevalence in, 34
- glucocorticoids excess, 36, 138
- glucose intolerance associated
  - with, 33–36
- inferior petrosal sinus (IPS)
  - sampling, 34, 34t, 35
- intraglandular ACTH-producing
  - microadenoma concern, 35
- ketoconazole monotherapy for
  - glycemic control in, 35
- laboratory testing results, 33
- pituitary exploration, 35
- treatment for, 34–36

## cystic fibrosis (CF)

- cystic fibrosis-related diabetes (CFRD) complication from, 156, 159
- cystic fibrosis-related diabetes (CFRD) pulmonary
  - functioning worsening, 157

## cystic fibrosis transmembrane

- conductance regulator (CFTR)
  - modulator
    - β-cell dysfunction from, 159–160
  - for cystic fibrosis-related diabetes (CFRD) glycemic control, 158–159

## cystic fibrosis-related diabetes

- (CFRD), 159
  - catabolism as result of, 156, 157
  - complications associated with, 157
  - cystic fibrosis (CF) mortality and, 156
  - insulinopenia result, 156
  - multifactorial pathophysiology of, 156
  - prevalence of, 156
  - pulmonary function worsening
    - from, 157

## cystic fibrosis-related diabetes

- (CFRD), cystic fibrosis
  - transmembrane conductance

## regulator (CFTR) modulator on

- glycemic control, 158–159
  - clinical problems from, 160
  - continuous glucose monitoring (CGM) and, 158, 159
  - laboratory test results, 158, 159
  - PROMISE observational study
    - on, 160
  - Trikafta treatment, 158, 159
- cystic fibrosis-related diabetes (CFRD), insulin therapy role in, 155
- laboratory test results, 155
  - only recommended treatment for, 156–157
  - pulmonary function and weight
    - decline, 155, 156f, 157

**D**dextrose, as hypoglycemia mainstay
 

- treatment, 147

diabetes. *See also* type 1 diabetes

- (T1D); type 2 diabetes (T2D)
  - cardiovascular disease prevalence
    - with, 199–201
  - COVID-19 risk factor of, 177
- Cushing's Disease (CD)
  - prevalence of, 34
- glucocorticoid-induced, 137, 138t
- ketogenic diet (KD) advocated
  - for, 73, 74
- steroid-induced, 35
- as Sweet's syndrome trigger, 27
- systemic lupus erythematosus (SLE) comorbidity with, 111, 112, 120

## diabetes, unusual type, 12–13

- GAD65 trends, 13t
- patient characteristics, 13t
- diabetes management, for ventricular
  - assist device (VAD) implantation, 199, 200–201

## diabetes progression

- in latent autoimmune diabetes in
  - adults (LADA), 14
- in Maturity-Onset Diabetes of the
  - Young (MODY)-4, 6–7

- diabetes types
    - appropriate pharmacological therapy for, 10
    - characteristics comparison, 10t
    - classification of, 14t
    - genetic testing importance, 11
  - diabetes-related complications, of
    - Maturity-Onset Diabetes of the Young (MODY)-4, 5
  - diabetic ketoacidosis (DKA), 20
    - acetoacetic acid,  $\beta$ -hydroxybutyric acid, and acetone.ketones accumulation, 60
    - acromegaly presenting with, 47–48, 48f, 49
    - characteristics of and defects in, 67
    - in end-state renal disease (ESRD), 66
    - histiocytosis-lymphadenopathy plus (HLP) syndrome, 42–43
    - hyperglycemia and, 49, 67, 68
    - with preserved renal function, 68
    - rapid-onset type 1 diabetes (T1D), 50, 51
    - from severe insulin deficiency, 48, 49
    - sodium-glucose cotransporter 2 (SGLT2) inhibitors and ketone body production, 72
    - type 1 diabetes (T1D) age and presentation of, 22
    - Wolcott-Rallison syndrome (WRS) and, 30
  - diabetic kidney disease, type 1 diabetes (T1D) risk for, 180–182, 181f
  - dietary recommendations, of American Diabetes Association (ADA), 73
  - dipeptidyl peptidase-4 inhibitors,
    - bullous pemphigoid association with, 28
  - Down's syndrome
    - continuous glucose monitoring (CGM) and type 1 diabetes (T1D) with, 123–124, 124t, 125
    - inability to express hypoglycemia symptoms, 124
    - type 1 diabetes (T1D) prevalence in, 124
  - Drug-induced Sweet's syndrome, 26, 27t
  - durvalumab, for immune checkpoint inhibitor (ICI) induced diabetes, 83
- ## E
- encephalitis complications, of Sweet's syndrome, 26
  - endocrinopathy
    - immune checkpoint inhibitor (ICI) therapy cause of, 51, 52
    - irreversible, 51
  - endoscopic ultrasound (EUS), 20, 21
  - end-stage renal disease (ESRD),
    - diabetic ketoacidosis (DK) in, 66
    - complications risk from, 66–67
    - diagnosis challenge in, 68, 69
    - hypokalemia and
      - hypophosphatemia, 67–68
    - hypovolemia in, 67–68
    - laboratory test results for, 66, 67t
    - lower insulin infusion rate for, 68, 69
    - management guidelines absence, 67
    - management recommendations, 69t
    - metabolic acidosis rapid development in, 67
    - treatment for, 66, 67t
  - Enriching New-Onset Diabetes for Pancreatic Cancer (END-PAC) model, 21
  - eosinophilic vasculitis, high-dose steroids treatment for, 37
  - euglycemic diabetic ketoacidosis (eDKA), 67
    - causes of, 63
    - diagnosis challenge for, 72
    - diagnostic criteria for, 55
    - precipitants for, 56, 72
    - recovery with recognition and appropriate treatment, 64

euglycemic diabetic ketoacidosis (eDKA), after ketogenic diet (KD) with type 2 diabetes (T2D) on sodium-glucose cotransporter 2 (SGLT2) inhibitor, 62  
 clinical signs and symptoms  
   recognition failure, 63–64  
 laboratory test results, 62  
 mechanisms from, 63  
 presentation of, 62, 63  
 subarachnoid hemorrhage, 62, 63, 64

euglycemic diabetic ketoacidosis (eDKA), due to sodium-glucose cotransporter 2 (SGLT2) inhibitor use, 58–59  
 challenges of, 60  
 immunotherapy-induced type 1 diabetes concern, 58–59  
 laboratory test results, 58, 59t  
 low-carbohydrate diets caution, 60  
 presentation of, 58  
 urine and serum ketones  
   monitoring for, 60, 61, 64

euglycemic diabetic ketoacidosis (eDKA), with COVID-19 infection  
 laboratory test results, 54  
 metabolic profile trends, 55f  
 presentation of, 54  
 with sodium-glucose cotransporter 2 inhibitor use, 54–55  
 treatment for, 54–55, 56, 57

euglycemic diabetic ketoacidosis (eDKA) with type 1 diabetes (T1D) treated with sodium-glucose cotransporter 2 (SGLT2) inhibitor while on ketogenic diet (KD), 71–72  
 basal-bolus insulin therapy for, 71  
 continuous glucose monitor (CGM) for, 72, 74  
 laboratory test results, 71, 72t  
 presentation of, 71  
 serum changes graphic representation, 73f

treatment of, 71–72

Evaluating U-500R Infusion Versus Injection in Type 2 Diabetes (VIVID) study  
 continuous subcutaneous insulin infusion (CSII) settings  
   protocol, 128–129  
 nocturnal hypoglycemia  
   observation, 128

## F

Faisalabad histiocytosis classification, of histiocytosis-lymphadenopathy plus (HLP) syndrome, 43  
 faster-acting insulin aspart (FiAsp), 129, 130f  
 fasting hypoglycemia, in Roux-en-Y gastric bypass (RYGB) patients, 143–145  
 fetal malformation related to obesity and type 2 diabetes (T2D), 184  
   increased folate before and during pregnancy, 184–186  
   of neural tube defect (NTD), 184–186  
   preconception counseling importance, 185, 186  
 folate intake, before and during pregnancy, 184–186  
 FOLFIRINOX chemotherapy, for pancreatic adenocarcinoma, 20  
 Food and Drug Administration (FDA), U.S.  
   durvalumab approved immunotherapy by, 83  
   phosphatidylinositol 3-kinase (PI3K) inhibition approval by, 87  
   Trikafta approval by, 160  
 Fournier's gangrene, sodium-glucose cotransporter 2 (SGLT2) inhibitors association with, 28  
 fractures, Wolcott-Rallison syndrome (WRS) and multiple, frequent, 31  
 fulvestrant with phosphatidylinositol 3-kinase (PI3K) inhibitor, for breast cancer, 90, 93

## G

- GAD65 antibodies, 8, 9, 12, 72
  - autoimmune (AI) diabetes and, 118
  - immune checkpoint inhibitor (ICI) therapy and anti-, 52, 78
  - in neurologic diseases, 119
  - seroconversion of, 119, 120
  - systemic lupus erythematosus (SLE) increase in, 120
  - trends, 13t
- GCK gene mutation, in Maturity-Onset Diabetes of the Young (MODY)-2, 39
- gemcitabine, for pancreatic adenocarcinoma, 20–21
- gene therapy research, on Maturity-Onset Diabetes of the Young (MODY)-4, 6
- genetic testing, 2, 5
  - diabetes types importance of, 11
  - glucokinase mutation, 37
  - heterozygous IPF1 mutation, 6
  - homozygous mutation in the EIF2AK3 gene, 29
  - PIK3CA mutation, 86
  - R122H PRSS1 (protease serine 1) variant, 16, 18
  - SLC29A3 gene mutation, 43, 45
- gestational diabetes, 107
  - Maturity-Onset Diabetes of the Young (MODY)-4 presenting as, 5
  - ongoing indefinite screening with history of, 108
- glucagon-like peptide-1 (GLP-1) agonist
  - for immune checkpoint inhibitor (ICI) diabetes, with partial  $\beta$ -cell destruction, 81–82
  - liraglutide as, 82
- glucagon-like peptide-1 receptor agonist (GLP-1RA) treatment
  - benefits of, 193
  - cardiovascular protection from, 165, 193
  - for Maturity-Onset Diabetes of the Young (MODY)-5 (MODY-HNF1B), 3
  - for type 2 diabetes (T2D) and rethinking insulin, 192–193
- glucagon-like peptide-1 receptor agonists (GLP-IRAs), type 2 diabetes (T2D) on high-dose insulin therapy effects, 164, 171–172, 192–193
  - cautions for, 172–173
  - continuous glucose monitoring (CGM) for, 171–172
  - patient education importance, 173–174
  - risks for, 173
  - treatment with, 171–172
- glucagon-like peptide 1 receptor agonists (GLP-IRAs) treatment
  - basal-bolus insulin therapy transition to, 163–164
  - cardiovascular benefits of, 165, 193
  - type 2 diabetes (T2D) management by, 164, 171–172, 173–174, 192–193
- glucocorticoid therapy
  - for inflammatory and autoimmune diseases treatment, 135
  - prednisone as, 136–137f, 137, 138
- glucocorticoid-induced diabetes, 137, 138t
- glucocorticoids excess, Cushing's Disease and, 36, 138
- glucocorticoid-treated patient, continuous glucose monitoring (CGM) of, 135, 136–137t, 136–139, 140f
- glucose homeostasis, phosphatidylinositol 3-kinase (PI3K)/AKT pathway for, 93, 94
- glucose intolerance associated with Cushing's Disease (CD), 33–36
- glucose tablets, 189
- glycemic control

insulin regimen simplification for  
 elderly patients and  
 improvement in, 167–168  
 ketoconazole monotherapy for  
 Cushing's Disease (CD), 35  
 granulocyte colony-stimulating factor  
 (G-CSF) treatment  
 for Wolcott-Rallison syndrome  
 (WRS), 29, 30, 31  
 Graves' hyperthyroidism, 12  
 growth retardation  
 histiocytosis-lymphadenopathy  
 plus (HLP) syndrome and, 42  
 Wolcott-Rallison syndrome  
 (WRS) and, 30, 31

## H

### H syndrome

clinical characteristics and  
 presentation of, 44–45t  
 hyperpigmentation of, 42–46, 43f  
 sensorineural hearing loss of,  
 42–46  
 type 1 diabetes (T1D) of, 42–46  
 Hashimoto's thyroiditis, 9, 179  
 HbA1c (A1C), IGF-1 levels linear  
 relationship with, 48, 48f, 49  
 hepatocyte nucleotide factor 1B  
 (HNF1B), Maturity-Onset  
 Diabetes of the Young (MODY)  
 and, 3  
 hereditary pancreatitis  
 pancreatic cancer and, 18  
 R122H PRSS1 (protease serine 1)  
 variant and, 16, 18  
 heroin, insulin and, 202–203  
 heterozygous IPF1 mutation,  
 Maturity-Onset Diabetes of the  
 Young (MODY)-4 and, 5, 6  
 histiocytosis-lymphadenopathy plus  
 (HLP) syndrome  
 diabetic ketoacidosis (DKA) and,  
 42–43  
 Faisalabad histiocytosis  
 classification, 43  
 growth retardation and, 42  
 H syndrome classification, 43–46

hyperpigmented area and, 42–46,  
 43f  
 laboratory tests for, 42  
 pigmented hypertrichosis with  
 insulin-dependent diabetes  
 (PHID) classification, 43  
 Rosai-Dorfman disease  
 classification, 43  
 SLC29A3 gene mutation, 43, 45  
 histopathology slide, of Sweet's  
 syndrome, 26f  
 homozygous IPF1 mutation, neonatal  
 pancreatic agenesis and, 6  
 homozygous mutation in the  
 EIF2AK3 gene, in Wolcott-  
 Rallison syndrome (WRS), 29, 30,  
 31  
 hybrid closed-loop system, as  
 automated insulin infusion  
 system, 134  
 hyperglycemia, 2  
 COVID-19 and persistent, 175  
 diabetic ketoacidosis (DKA) and,  
 49, 67, 68  
 diet modification for, 101  
 medication considerations, 93  
 metformin as first-line treatment  
 for, 93  
 pancreatic  $\beta$ -cell dysfunction and,  
 10, 81, 84  
 phosphatidylinositol 3-kinase  
 (PI3K) inhibition side effect,  
 87, 88  
 recurrent, 15  
 sodium-glucose cotransporter 2  
 (SGLT2) inhibitors for  
 management of, 101, 102  
 stress, 176, 177  
 hyperglycemia from oral comfort  
 feeds, 188–189  
 laboratory test results, 188  
 oral mucosa evaluation in, 189  
 of patient with mental health and  
 polysubstance abuse  
 concerns, 188–189  
 presentation of, 188



hyperinsulemic hypoglycemia after  
 Roux-en-Y gastric bypass (RYGB)  
 surgery, 143–144  
 fasting and postprandial, 143–145  
 low-carbohydrate diet or low-  
 carbohydrate mixed meals  
 for, 144  
 nesidioblastosis of patient, 143,  
 144, 145  
 patient pancreatectomy, 144  
 selective arterial calcium  
 stimulation testing, 145  
 hyperinsulinemia, in Maturity-Onset  
 Diabetes of the Young (MODY)-  
 4, 6, 7  
 hyperpigmented area, in histiocytosis-  
 lymphadenopathy plus (HLP)  
 syndrome, 42–46, 43f  
 hypoglycemia, 12  
 alcohol use and, 146, 148  
 continuous glucose monitoring  
 (CGM) for Down's syndrome  
 adult episodes of, 123–125  
 dextrose as mainstay treatment  
 for, 147  
 Down's syndrome inability  
 express symptoms of, 124  
 Evaluating U-500R Infusion  
 Versus Injection in Type 2  
 Diabetes (VIVID) study  
 observation of nocturnal, 129  
 in hospitalized patients and  
 glucose tablets, 189  
 medication interactions and, 151  
 pancreatogenic (Type 3c) diabetes  
 higher risk for, 18  
 hypokalemia, 33  
 in diabetic ketoacidosis (DK) in  
 end-stage renal disease  
 (ESRD), 67–68  
 hypophosphatemia, in diabetic  
 ketoacidosis (DK) in end-stage  
 renal disease (ESRD), 67–68  
 hypothyroidism  
 immune checkpoint inhibitor  
 (ICI) diabetes, with partial  
 $\beta$ -cell destruction and, 81, 82,  
 85

Na-l-thyroxine supplementation  
 for treatment of, 30  
 type 1 diabetes (T1D) and aging  
 risk for, 112

## I

immune checkpoint inhibitor (ICI)  
 diabetes, with partial  $\beta$ -cell  
 destruction, 80  
 clinical course for, 81–82, 81f  
 glucagon-like peptide-1 (GLP-1)  
 agonists for, 81–82  
 hypothyroidism and, 81, 82, 85  
 pembrolizumab effect on blood  
 glucose levels, 81–82, 81f  
 presentation and laboratory test  
 results for, 80  
 immune checkpoint inhibitor (ICI)  
 induced diabetes, 83  
 $\beta$ -cell function recovery, 84  
 characteristics for, 84  
 continuation of immunotherapy  
 challenge, 84, 85  
 continuous glucose monitoring  
 (CGM) for, 83  
 diabetes education for, 83, 84  
 diagnosis for, 83  
 durvalumab Food and Drug  
 Administration (FDA)-  
 approved immunotherapy for,  
 83  
 insulin as mainstay treatment  
 from, 78, 84, 85  
 laboratory test results, 83  
 manifestations of, 84  
 immune checkpoint inhibitor (ICI)  
 induced type 1 diabetes (T1D), 77  
 insulin therapy requirement, 78,  
 84, 85  
 laboratory test results, 77  
 presentation and treatment, 77  
 risk assessment strategies for, 78  
 immune checkpoint inhibitor (ICI)  
 insulinopenic diabetes, rapid-  
 onset, 50–51  
 immune checkpoint inhibitor (ICI)  
 therapy

- anti-GAD65 predominance and, 52, 78
  - autoimmune (AI) diabetes due to, 51–52, 61, 80–81, 84
  - endocrinopathy caused by, 51, 52
  - hypothyroidism side effect of, 81, 82, 85
  - malignancies management by, 50–51, 52, 77–78
  - PD-1 and CTLA-4, 51, 77–78, 83, 85
  - Immunology of Diabetes Society, 10
  - immunotherapy-induced type 1 diabetes, 58–59
  - inferior petrosal sinus (IPS), Cushing's Disease (CD) sampling, 34, 34t, 35
  - inflammatory diseases, glucocorticoid therapy for, 135
  - inflammatory skin condition, Sweet's syndrome as, 27
  - insulin allergy
    - first-line management for, 105
    - local reactions to, 104
    - to subcutaneous (SQ) insulin, 103
  - insulin and heroin patient, 202–203
    - Medtronic G670 pump, 202–203
    - presentation, 202
  - insulin autoantibodies (IAAs), 9
  - insulin deficiency, diabetic ketoacidosis (DKA) from, 48, 49
  - insulin insensitivity, from Cushing's Disease (CD), 34, 35
  - insulin overdose
    - corticosteroids for, 147
    - non-pharmacological therapies for, 147–148
    - refractory hypoglycemia due to massive unintentional, 146–147
  - insulin receptor antibodies (AIRAs) testing, 98, 100f, 101
  - insulin regimen simplification, for elderly patients with type 2 diabetes (T2D), 167–168
    - glycemic control improvement from, 167–168
  - insulin resistance (IR)
    - features and risk factors for, 116
    - obesity-related, 172
    - transient severe, in COVID-19 and prediabetes, 175–177
  - insulin therapy, 5
    - for immune checkpoint inhibitor (ICI) induced type 1 diabetes (T1D), 78, 84, 85
    - for pancreatogenic (Type 3c) diabetes, 17, 18
    - role in cystic fibrosis-related diabetes (CFRD), 155–157
  - insulinopenia
    - cystic fibrosis-related diabetes (CFRD) and, 156
    - PD-1 role in immune checkpoint inhibitor (ICI) insulinopenic diabetes, 51, 77–78, 83, 85
  - insulin-sensitizing role, of opioids, 203
  - intraglandular ACTH-producing microadenoma, Cushing's Disease (CD) and, 35
  - islet cell autoantibodies (ICAs), 5, 8, 9, 109f, 118
  - systemic lupus erythematosus (SLE) increase of, 120
- ## K
- ketoacidosis. *See* diabetic ketoacidosis (DKA)
  - ketoconazole monotherapy, for Cushing's Disease (CD) glycemic control, 35
  - ketogenic diet (KD)
    - advocated for diabetes, 73
    - effectiveness of sodium-glucose cotransporter 2 (SGLT2) inhibitors and, 87, 88
- ## L
- late dumping syndrome, 144
  - latent autoimmune diabetes in adults (LADA), 2, 9, 10, 108, 109f
    - autoimmune markers for, 115
    - disease progression in, 14
    - features of, 13

- immune checkpoint inhibitor (ICI) induced diabetes
  - differentiated from, 84
- personalized treatment approach for, 116
- within type 1 diabetes (T1D)
  - classification, 116
- as type 1.5 diabetes, 13
- type 2 diabetes (T2D)
  - differentiation from, 13
- latent autoimmune diabetes in adults (LADA), with insulin allergy, 103–104
  - hospital course of treatment for, 104
  - laboratory test results, 103
  - physical exam for, 104
  - presentation of, 103–104
- lifestyle modifications, for Maturity-Onset Diabetes of the Young (MODY)-4, 6
- liraglutide, as glucagon-like peptide-1 (GLP-1) agonist, 82
- low-carbohydrate diets
  - alpelisib-induced hyperglycemia and, 87
  - caution for euglycemic diabetic ketoacidosis (eDKA), due to sodium-glucose cotransporter 2 (SGLT2) inhibitor use, 60
  - for hyperinsulinemic hypoglycemia, 144
  - type 2 diabetes (T2D) and, 63
- lung cancer, 77–78, 83–85, 86–88
- lupus. *See also* systemic lupus erythematosus (SLE)
  - autoimmune (AI) diabetes from flare of, 118, 119t
  - pneumonitis, 118
  - type B insulin resistance (TBIR) with nephritis of, 97–98, 98t, 99f, 100–102, 100f

## M

- Malignancy-associated Sweet's syndrome, 26, 27t

- Maturity-Onset Diabetes of the Young (MODY)
  - as autosomal-dominant familial diabetes, 38
  - criteria for, 38
  - genetic testing glucokinase mutation for, 37
  - hepatocyte nucleotide factor 1B (HNF1B) role in, 3
  - identified gene mutations of, 38–39
  - misdiagnosis of, 38
  - pancreatic  $\beta$ -cell dysfunction, 3
  - single-gene mutations, 3
  - steroid-induced diabetes misdiagnosis of, 37
- Maturity-Onset Diabetes of the Young (MODY)-2, CK gene mutation, 39
- Maturity-Onset Diabetes of the Young (MODY)-4
  - diabetes progression in, 6–7
  - diabetes-related complications, 5
  - gestational diabetes presenting as, 5
  - heterozygous IPF1 mutation, 5, 6
  - lifestyle modification for, 6
  - limited treatment strategies reports for, 6
  - medication intolerance, 5
  - metformin treatment for, 6
  - obesity and hyperinsulinemia in, 6, 7
  - oral antihyperglycemic agents for, 6
- Maturity-Onset Diabetes of the Young (MODY)-5 (MODY-HNF1B)
  - 17q12 deletion syndrome, 3
  - genetic testing for, 2, 3
  - glucagon-like peptide-1 receptor agonist (GLP-1RA) treatment for, 3
  - monotherapy with metformin response, 2–3
  - mutation presentations in, 3
- MDI Liraglutide Trial, 164–165
- meal bolus need via continuous subcutaneous insulin infusion

(CSII) pump, U-500 regular (U-500R) insulin, 129–130

Medical Research Council (MRC) study, on obesity and NTD risk, 185

Medtronic 670G insulin pump, 5, 7, 202–203

melanoma cancer, 80–82

meningitis complications, of Sweet's syndrome, 26

mental health concerns, comfort food intake and, 188–189

metabolic acidosis, 67

metabolic trends, of euglycemic diabetic ketoacidosis (eDKA) with COVID-19 infection, 55f

metformin treatment, 8

  for alpelisib-induced hyperglycemia, 86, 88

  as hyperglycemia first-line, 93

  for Maturity-Onset Diabetes of the Young (MODY)-4, 6

  for Maturity-Onset Diabetes of the Young (MODY)-5 (MODY-HNF1B), 2–3

  against pituitary corticotroph tumors, 35

  for steroid-induced diabetes, 37

  for type 2 diabetes (T2D), 33

MiniMed 670G automated insulin infusion system, 132, 133, 134

mixed-density/hypo-enhancing mass, pancreatic adenocarcinoma and, 20

monotherapy with metformin, Maturity-Onset Diabetes of the Young (MODY)-5 (MODY-HNF1B) response to, 2–3

multiple daily insulin (MDI) injections, 163

  MDI Liraglutide Trial on, 164–165

mutation presentations, in Maturity-Onset Diabetes of the Young (MODY)-5 (MODY-HNF1B), 3

## N

Na-l-thyroxine supplementation treatment, for hypothyroidism, 30

National Birth Defects Prevention Study, 185

National Institutes of Health (NIH) protocol for, type B insulin resistance (TBIR), with lupus nephritis and autoimmune hepatitis, 98, 100, 101

nephritis, 118

  type B insulin resistance (TBIR) with lupus, 97–98, 98t, 99f, 100–102, 100f

nesidioblastosis, 143, 144, 145

neural tube defect (NTD), of fetus, 184–186

neurologic manifestations with high GAD65 antibodies, 119 of Sweet's syndrome, 26

neuropathy

  peripheral, Sweet's syndrome and, 23, 26

  treatment-induced neuropathy of diabetes (TIND), 197

  type 1 diabetes (T1D), with worsening, 195, 196, 197

  type and severity testing, 196

new-onset diabetes, pancreatic cancer and, 20–22

nondiabetic renal disease (NDRD) in type 1 diabetes (T1D), renal biopsy and, 179–180, 181–182, 181f

  laboratory test results, 179, 180

  treatment, 179

nutrition therapy. *See also* ketogenic diet (KD); low-carbohydrate diets for pancreatogenic (Type 3c) diabetes, 17, 18

## O

obesity

  childhood, 9

  COVID-19 risk factor of, 177

- fetal malformation due to type 2 diabetes (T2D) and, 184–186
  - insulin resistance related to, 172
  - in Maturity-Onset Diabetes of the Young (MODY)-4, 6, 7
  - pregnancy complications and, 184–186
  - Roux-en-Y gastric bypass surgery (RYGB) for, 143–145
  - type 2 diabetes (T2D) and rethinking insulin, 191–193
  - octreotide
    - for sulfonyleurea and antibiotic use, 152
    - for sulfonyleurea overdose, 147
  - opioids
    - behavioral changes from abuse of, 204
    - insulin-sensitizing role of, 203
    - withdrawal, 188
  - oral antihyperglycemic agents, for Maturity-Onset Diabetes of the Young (MODY)-4, 6
  - oral comfort feeds, hypoglycemia from, 188–189
  - oral mucosa evaluation, for hyperglycemia, 189
  - osteoporosis, pamidronate treatment for, 30
  - overnight hypoglycemia, 118, 123, 127, 199
- P**
- pamidronate treatment
    - for osteoporosis, 30
    - for Wolcott-Rallison syndrome (WRS), 30
  - pancreatectomy, 16, 18
    - of Roux-en-Y gastric bypass (RYGB) patient, 144
  - pancreatic adenocarcinoma
    - computed tomography (CT) scan for, 20, 21, 22
    - CPDPC study on, 22
    - endoscopic ultrasound (EUS) for, 20
    - FOLFIRINOX chemotherapy, 20
    - mixed-density/hypo-enhancing mass, 20
    - radiation therapy for clival metastasis, 21
    - treatment for, 20–21
  - pancreatic  $\beta$ -cell dysfunction
    - Cushing's Disease (CD) increase of, 34
    - from cystic fibrosis transmembrane conductance regulator (CFTR), 159–160
    - hyperglycemia and, 10, 81, 84
    - latent autoimmune diabetes in adults (LADA) therapy for, 14
    - of Maturity-Onset Diabetes of the Young (MODY), 3
    - pancreatic cancer and, 21
    - from plasma glucose decrease, 147
  - pancreatic cancer
    - diabetes as risk factor for, 21
    - as form of pancreatogenic (Type 3c) diabetes, 22
    - hereditary pancreatitis, 18
    - new-onset diabetes and, 20–22
  - pancreatic enzyme replacement therapy, for pancreatogenic (Type 3c) diabetes, 16, 17, 18
  - pancreatic exocrine insufficiency, 17, 22
  - pancreatogenic (Type 3c) diabetes, 16–17
    - abdominal pain and, 16
    - hypoglycemia risk, 18
    - insulin administration timing, 18
    - insulin therapy, 17, 18
    - laboratory studies and vitamin levels, 16–17
    - nutrition therapy for, 17, 18
    - oral pancreatic enzyme replacement therapy for, 16, 17, 18
    - pancreatic cancer diabetes form of, 22
    - pancreatic exocrine insufficiency and, 17
    - postprandial nausea, 16
    - pregnancy and, 16

- vitamin supplements treatment, 17
- PD-1 role, in immune checkpoint inhibitor (ICI) insulinopenic diabetes, 51, 77–78, 83, 85
- pembrolizumab, blood glucose levels effect from, 81–182, 81f
- peripheral neuropathy, Sweet's syndrome and, 23, 26
- pharmacological therapy, diabetes types and appropriate, 10
- phosphatidylinositol 3-kinase (PI3K) inhibition
  - due to alpelisib therapy, 87
  - Food and Drug Administration (FDA) approval for, 87
  - with fulvestrant, for breast cancer, 90, 93
  - hyperglycemia side effect of, 87, 88
  - manifestations of, 87
- phosphatidylinositol 3-kinase (PI3K) inhibitor-induced hyperglycemia, 90
  - glycemic control on insulin
    - glargine 10 units daily, 90, 91f
  - glycemic control on insulin
    - glargine 20 units daily, 92f
  - laboratory tests results, 90
  - treatment for, 90
- photosensitivity role, in Sweet's syndrome, 26
- PI3K/AKT pathway
  - activating mutations in cancers, 94
  - cellular physiology role of, 90
  - for glucose homeostasis, 93, 94
  - insulin reactivation research on, 94
  - side effects for inhibition of, 94
- pigmented hypertrichosis with insulin-dependent diabetes (PHID)
  - classification, of histiocytosis-lymphadenopathy plus (HLP) syndrome, 43
- PIK3CA mutation, alpelisib-induced hyperglycemia and, 86
- pituitary corticotroph tumors, metformin against, 35
- pituitary exploration, Cushing's Disease (CD) and, 35
- pituitary macro-adenoma, 47
- PKR-like ER kinase (PERK)
  - expression loss, in Wolcott-Rallison syndrome (WRS), 30, 31
- plasma glucose, pancreatic  $\beta$ -cell dysfunction from decrease in, 147
- polysubstance abuse
  - comfort food intake and, 188–189
  - opioids, 188, 203, 204
- positive GAD antibodies, autoimmune (AI) diabetes onset during pregnancy and, 109, 109f
- postpartum pregnancy, antibody-positive diabetes and, 108
- postprandial hypoglycemia, in Roux-en-Y gastric bypass (RYGB) patients, 143–145
- potassium chloride, for hypokalemia treatment, 68
- potassium supplements, for Cushing's Disease (CD), 34, 36
- prednisone, as glucocorticoid therapy, 137
  - chronic obstructive pulmonary disorder (COPD)
    - exacerbation from, 138
  - continuous glucose monitor (CGM) report before and after, 136f–137f
- pregnancy
  - autoimmune (AI) diabetes onset during, 107, 108–109, 109f
  - gestational diabetes during, 5, 107, 108
  - increased folate before and during, 184–186
  - obesity and complications of, 184–186
  - pancreatogenic (Type 3c) diabetes and, 16
- Preventive Services Task Force, U.S., on pancreatic cancer screening, 21
- PROMISE observational study, on Trikafta, 160

protein tyrosine phosphatase (IA-2), 9

## R

- R122H PRSS1 (protease serine 1)
  - variant, hereditary pancreatitis and, 16, 18
- radiation therapy, for clival metastasis, 21
- rapid-onset type 1 diabetes (T1D) and diabetic ketoacidosis (DK), 50
  - immune checkpoint inhibitor (ICI) insulinopenic diabetes, 50–51
  - stage IV clear cell carcinoma and, 50
- refractory hypoglycemia, due to
  - massive unintentional insulin overdose, 146–147
  - alcohol use and, 146, 148
  - corticosteroids for, 147
  - laboratory test results, 146–147, 147f
  - seizures from, 146
  - treatment, 146–147, 148
- refractory hypoglycemia, due to
  - sulfonylurea and antibiotic use, 150–151
  - antibiotics associated with, 151–152, 151t
  - laboratory test results, 150, 151
  - medication interactions and, 151
  - treatment, 150–151
- renal biopsy, for nondiabetic renal disease (NDRD) in type 1 diabetes (T1D), 179–180, 181–182, 181f
- Rosai-Dorfman disease, of
  - histiocytosis-lymphadenopathy plus (HLP) syndrome, 43
- Roux-en-Y Gastric Bypass Surgery (RYGB) surgery, hyperinsulemic hypoglycemia after, 143–144, 145

## S

- selective arterial calcium stimulation testing, 145

- sensorineural hearing loss, of H syndrome, 42–46
- seroconversion, of GAD65 antibodies, 119, 120
- 17q12 deletion syndrome, Maturity-Onset Diabetes of the Young (MODY)-5 (MODY-HNF1B) and, 3
- skin lesions of Sweet's syndrome, topical triamcinolone therapy for, 23, 26
- SLC29A3 gene mutation,
  - histiocytosis-lymphadenopathy plus (HLP) syndrome and, 43, 45
- sodium-glucose cotransporter 2 (SGLT2) inhibitors
  - discontinuance reasons for, 56, 59–60
  - effectiveness of ketogenic diet (KD) and, 87, 88
- euglycemic diabetic ketoacidosis (eDKA) complication from, 54–55, 62–64
- euglycemic diabetic ketoacidosis (eDKA) development
  - mechanisms of, 56, 58–60, 59t
- euglycemic diabetic ketoacidosis (eDKA) with type 1 diabetes (T1D) while on ketogenic diet (KD), 71–72, 72t, 73f, 74
- Fournier's gangrene association with, 28
- for hyperglycemia management, 101, 102
- ketonic state and dehydration from, 73, 74
- with phosphatidylinositol 3-kinase (PI3K) inhibitors use, 93
- serum ketone measurement for symptoms, 64
- type 2 diabetes (T2D) and
  - ketogenic diet (KD), 62–64, 71
- type 2 diabetes (T2D) treatment with, 55
- spironolactone, for Cushing's Disease (CD), 34, 36

starvation ketosis, 56  
 steroid treatments, for eosinophilic vasculitis, 37  
 steroid-induced diabetes, 35  
   laboratory tests for, 37, 38t  
   Maturity-Onset Diabetes of the Young (MODY) misdiagnosis as, 37  
 stress hyperglycemia, 176, 177  
 subarachnoid hemorrhage, 62, 63, 64  
 subclassification stages, of type 1 diabetes (T1D), 10  
 subcutaneous (SQ) insulin, allergy to, 103  
 sulfonylurea  
   octreotide use in overdoses, 147  
   refractory hypoglycemia due to use of, 150–152  
   type 2 diabetes (T2D) therapy of, 33  
 Sweet's syndrome, 23–26  
   Classic Sweet's syndrome, 26, 27t  
   corticosteroids challenge to, 27, 28  
   diabetes as trigger for, 27  
   Drug-induced Sweet's syndrome, 26, 27t  
   etiologies and causes of, 27t  
   as inflammatory skin condition, 28  
   laboratory data, 23, 24–25t  
   Malignancy-associated Sweet's syndrome, 26, 27t  
   meningitis and encephalitis complications, 26  
   neurologic manifestations of, 26  
   peripheral neuropathy and, 23, 26  
   photosensitivity role in, 26  
   skin lesions, 23, 25f, 26  
   treatment for, 27  
   triamcinolone topical therapy, 23, 26  
   typical histopathology slide of, 26f  
 systemic lupus erythematosus (SLE)  
   and diabetes comorbidity, 111  
   GAD65 and islet cell autoantibodies (ICAs)  
     increase in, 120

laboratory test results and treatment, 111  
 presentation of, 111  
 type 1 diabetes (T1D) suspected diagnosis, 112

## T

thiamine-responsive megaloblastic anemia (TRMA) syndrome, 44  
 thyroid testing results, in Wolcott-Rallison syndrome (WRS), 30  
 thyroxine replacement, for Wolcott-Rallison syndrome (WRS), 30  
 transient severe insulin resistance, in COVID019 and prediabetes, 175, 177f  
 transporter 8 (ZnT8), 9  
 trans-sphenoidal pituitary resection, 47  
 treatment-induced neuropathy of diabetes (TIND), 197  
 triamcinolone therapy, for skin lesions, 23, 26  
 Trikafta, as cystic fibrosis transmembrane conductance regulator (CFTR), 158, 159  
   Food and Drug Administration (FDA) approval of, 160  
   PROMISE observational study on, 160  
 type 1 diabetes (T1D)  
   alcohol abuse and, 148  
   antibodies associated with, 9  
   autoimmune (AI) diabetes education, 108  
   autoimmune diseases with, 9, 112  
   characteristics of, 3  
   continuous glucose monitoring (CGM) and Down's syndrome, 123–124  
   C-peptide level in, 8  
   diabetic ketoacidosis (DKA) age and presentation, 22  
   diabetic kidney disease risk, 180–182, 181f  
   Down's syndrome prevalence of, 124



- Finnish Nationwide Study on autoimmune diseases with, 112
  - of H syndrome, 42–46
  - ketoacidosis presentation and age of, 22
  - ketogenic diet (KD) safety and efficacy research, 74
  - laboratory results, 9t
  - latent autoimmune diabetes in adults (LADA) within classification of, 116
  - nondiabetic renal disease (NDRD) and, 180–182
  - subclassification stages of, 10
  - systemic lupus erythematosus (SLE) suspected diagnosis of, 112
  - type 2 diabetes (T2D)
    - distinguished from, 8
  - Wolcott-Rallison syndrome (WRS) and early-onset, 30
  - type 1 diabetes (T1D), with worsening neuropathy, 195
    - carbohydrate ratio adjustment, 195
    - presentation of, 195
    - treatment, 195, 196
    - treatment-induced neuropathy of diabetes (TIND), 197
  - type 1.5 diabetes, latent autoimmune diabetes in adults (LADA) as, 13
  - type 2 diabetes (T2D)
    - American Diabetes Association (ADA) medical management algorithm on, 163
    - characteristics of, 3, 163
    - childhood obesity, 9
    - etiology and pathogenesis understanding, 115
    - insulin regimen simplification for elderly patients with, 167–168
    - ketogenic diet (KD) and euglycemic diabetic ketoacidosis (eDK), 62–64, 71
    - laboratory results, 9t
    - latent autoimmune diabetes in adults (LADA) differentiation from, 13
    - low-carbohydrate diets and, 63
    - metformin and sulfonylurea therapy for, 33
    - older patients misdiagnosis for, 74
    - sodium-glucose cotransporter 2 (SGLT2) inhibitors treatment for, 55
    - systemic lupus erythematosus (SLE) and, 120
    - type 1 diabetes (T1D)
      - distinguished from, 8
    - type 2 diabetes (T2D), rethinking insulin in, 191–192
    - glucagon-like peptide-1 receptor agonist (GLP-1RA) and, 192–193
    - obesity and, 191
    - treatment and laboratory test results, 191–192, 192t
  - type B insulin resistance (TBIR), with lupus nephritis and autoimmune hepatitis, 97–98
    - blood glucose and insulin trend, 99f
    - classic manifestation of, 100
    - high mortality of, 101
    - insulin receptor antibodies (AIRAs) testing, 98, 100f, 101
    - laboratory test results, 97, 98, 98t, 99f, 100, 100f
    - National Institutes of Health (NIH) protocol for, 98, 100, 101
    - onset characterizations, 102
    - patient characteristics for, 99
    - presentation of, 97
    - treatment management of, 101
- ## V
- ventricular assist device (VAD)
    - implantation, diabetic management of, 199, 201
    - complications of, 200
    - healthy lifestyle instructions, 200

vitamin supplements, for  
pancreatogenic (Type 3c) diabetes,  
17

## W

Wolcott-Rallison syndrome (WRS),  
29–30  
clinical features of, 30, 31  
early-onset type 1 diabetes (T1D)  
and, 30  
genetic testing, 29  
granulocyte colony-stimulating  
factor (G-CSF) treatment for,  
29, 30, 31  
growth retardation, 30, 31  
homozygous mutation in the  
EIF2AK3 gene, 29, 30, 31  
laboratory tests for, 29  
multiple frequent fractures and,  
31  
pamidronate treatment for, 30  
physical examination, 29  
PKR-like ER kinase (PERK)  
expression loss in, 30, 31  
thyroid testing results, 30  
thyroxine replacement for, 30